Company Molecular Partners AG

Equities

MOLN

CH0256379097

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Ratings for Molecular Partners AG

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Swiss Exchange Other stock markets 16:31:30 26/04/2024 BST			5-day change	1st Jan Change
3.36 ^CHF	+5.00%		-0.30%	-2.33%

03-15	Transcript : Molecular Partners AG, 2023 Earnings Call, Mar 15, 2024
03-15	Molecular Partners Swings to Loss in FY23; Revenue Down	MT

Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

Number of employees: 168

CHF in Million	2022	Weight	2023	Weight	Delta
Biopharmaceutical Products 100.0 %	190	100.0 %	7	100.0 %	-96.29%

CHF in Million	2022	Weight	2023	Weight	Delta
Switzerland 100.0 %	180	94.9 %	7	100.0 %	-96.09%

Managers	Title	Age	Since
Michael Tobias Stumpp FOU	Founder	52	22/11/04
Patrick Amstutz FOU	Founder	49	22/11/04
Michael Pitzner CMP	Compliance Officer	-	31/10/22
Alexander Zürcher COO	Chief Operating Officer	-	30/06/22
Philippe Legenne CTO	Chief Tech/Sci/R&D Officer	-	31/12/19
Daniel Steiner CTO	Chief Tech/Sci/R&D Officer	-	31/12/10
Baris Arican CTO	Chief Tech/Sci/R&D Officer	-	28/02/22
Seth D. Lewis IRC	Investor Relations Contact	-	31/10/19
Renate Gloggner HRO	Human Resources Officer	-	30/09/21

Members of the board	Title	Age	Since
William Burns CHM	Chairman	76	30/10/17
Steven Holtzman BRD	Director/Board Member	70	18/09/14
Vito Palombella BRD	Director/Board Member	61	31/03/20
Patrick Amstutz FOU	Founder	49	22/11/04
Agnete Brunsvik Fredriksen BRD	Director/Board Member	47	20/04/21
Michael Vasconcelles BRD	Director/Board Member	61	28/04/20
Sandipkumar S. Kapadia BRD	Director/Board Member	53	31/03/20
Dominik Höchli BRD	Director/Board Member	57	20/04/21

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	36,368,901	29,497,085 ( 81.11 %)	3,500,000 ( 9.624 %)	81.11 %

Name	Equities	%	Valuation
BVF Partners LP 23.91 %	8,696,205	23.91 %	35 M CHF
Suvretta Capital Management LLC 4.812 %	1,750,000	4.812 %	7 M CHF
NOVARTIS AG 4.782 %	1,739,130	4.782 %	7 M CHF
EcoR1 Capital, LLC 2.989 %	1,086,993	2.989 %	4 M CHF
Hansjörg Wyss 2.963 %	1,077,737	2.963 %	4 M CHF
GAM Investment Management (Switzerland) AG 2.935 %	1,067,288	2.935 %	4 M CHF
Michael Tobias Stumpp 2.110 %	767,524	2.110 %	3 M CHF
Patrick Amstutz 2.021 %	735,095	2.021 %	3 M CHF
Union Bancaire Privée, UBP SA 1.149 %	417,701	1.149 %	2 M CHF
ACATIS Investment Kapitalverwaltungsgesellschaft mbH 0.5503 %	200,137	0.5503 %	816 591 CHF

Name	Equities	%	Valuation
BVF, Inc. 1.219 %	443,221	1.219 %	2 M CHF
Suvretta Capital Management LLC 1.100 %	400,000	1.100 %	2 M CHF
Tang Capital Management LLC 0.2750 %	100,000	0.2750 %	404 000 CHF
G1 Execution Services LLC 0.0347 %	12,618	0.0347 %	50 977 CHF
Morgan Stanley Capital Services LLC 0.001009 %	367	0.001009 %	1 483 CHF
RhumbLine Advisers LP 0.000740 %	269	0.000740 %	1 087 CHF
Qube Research & Technologies Ltd. (France) 0.000044 %	16	0.000044 %	65 CHF
JPMorgan Securities LLC 0.000003 %	1	0.000003 %	4 CHF

Molecular Partners AG

Wagistrasse 14

8952, Schlieren

+41 44 755 77 00

http://www.molecularpartners.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.36 CHF

Average target price

9.35 CHF

Spread / Average Target

+178.27%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
MOLECULAR PARTNERS AG	-2.33%	121M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs